Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.
PD-1
VEGF
atezolizumab
durvalumab
hepatocellular carcinoma
tislelizumab
Journal
Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
02
2023
accepted:
29
08
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the fourth most frequent cause of cancer-related death worldwide. HCC frequently presents as advanced disease at diagnosis, and disease relapse following radical surgery is frequent. In recent years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced HCC, particularly with the introduction of atezolizumab/bevacizumab as the new standard of care for first-line treatment. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective first-line treatment for advanced HCC and most of the research is currently focused on developing combination treatments based mainly on ICIs. In this review, we will discuss the rationale and ongoing clinical trials of immune-based combination therapies for the treatment of advanced HCC, also focusing on new immunotherapy strategies such as chimeric antigen receptor T cells (CAR-T) and anti-cancer vaccines.
Identifiants
pubmed: 37701562
doi: 10.2147/JHC.S390963
pii: 390963
pmc: PMC10493094
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1445-1463Informations de copyright
© 2023 Carloni et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Dig Liver Dis. 2022 Nov;54(11):1563-1572
pubmed: 35906166
Gastroenterology. 2021 Sep;161(3):879-898
pubmed: 34126063
Int J Clin Oncol. 2010 Dec;15(6):552-8
pubmed: 20963618
Annu Rev Pathol. 2017 Jan 24;12:153-186
pubmed: 27959632
Immunol Rev. 2017 Mar;276(1):165-177
pubmed: 28258690
N Engl J Med. 2022 Jan 6;386(1):24-34
pubmed: 34986285
Cancer Immunol Immunother. 2018 Oct;67(10):1621-1634
pubmed: 30078052
Hepatol Int. 2022 Oct;16(5):1199-1207
pubmed: 35986846
J Exp Clin Cancer Res. 2019 Sep 9;38(1):396
pubmed: 31500650
PLoS One. 2019 Feb 27;14(2):e0212513
pubmed: 30811474
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Cancers (Basel). 2022 Oct 13;14(20):
pubmed: 36291802
Cancers (Basel). 2021 Nov 08;13(21):
pubmed: 34771745
Eur J Cancer. 2017 Apr;75:47-55
pubmed: 28214657
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3
pubmed: 29908364
Clin Cancer Res. 2021 Feb 15;27(4):1003-1011
pubmed: 33087333
Nat Med. 2022 Aug;28(8):1599-1611
pubmed: 35739268
Lancet Oncol. 2022 Jan;23(1):77-90
pubmed: 34914889
Int J Mol Sci. 2021 May 28;22(11):
pubmed: 34071550
Cancer Immunol Res. 2019 Nov;7(11):1813-1823
pubmed: 31484657
Gastroenterology. 2020 Jun;158(8):2250-2265.e20
pubmed: 32060001
Mol Med Rep. 2019 Oct;20(4):3773-3781
pubmed: 31485637
Eur J Cancer. 2022 Dec;177:175-185
pubmed: 36368251
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1245-1251
pubmed: 34431725
Front Oncol. 2022 Sep 02;12:958720
pubmed: 36119533
J Biomed Sci. 2023 Jan 4;30(1):1
pubmed: 36600243
Gastroenterology. 2015 Oct;149(4):1042-52
pubmed: 26052074
Cancers (Basel). 2020 Oct 27;12(11):
pubmed: 33121034
Clin Transl Sci. 2023 Aug;16(8):1445-1457
pubmed: 37165980
Front Immunol. 2017 Jan 11;7:690
pubmed: 28123387
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
World J Hepatol. 2015 Aug 18;7(17):2080-90
pubmed: 26301050
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
Gastroenterology. 2020 Aug;159(2):609-623
pubmed: 32275969
Cancer. 2019 Sep 15;125(18):3234-3241
pubmed: 31154669
J Hepatol. 2021 Sep;75(3):600-609
pubmed: 34051329
Oncoimmunology. 2016 Dec 23;6(1):e1261779
pubmed: 28197389
Cell. 2019 Oct 31;179(4):829-845.e20
pubmed: 31675496
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
J Hepatol. 2020 Dec;73(6):1460-1469
pubmed: 32710922
J Transl Med. 2014 Apr 05;12:86
pubmed: 24708667
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Cancers (Basel). 2020 Nov 16;12(11):
pubmed: 33207844
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
Front Cell Dev Biol. 2019 Oct 11;7:233
pubmed: 31681766
Cancer Res. 2014 Aug 1;74(15):4042-52
pubmed: 24812273
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Front Immunol. 2021 Apr 07;12:653836
pubmed: 33897701
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Natl Compr Canc Netw. 2021 May 1;19(5):541-565
pubmed: 34030131
Lancet Oncol. 2022 Aug;23(8):995-1008
pubmed: 35798016
Hepatology. 2021 Nov;74(5):2544-2560
pubmed: 34036623
World J Hepatol. 2015 Aug 28;7(18):2147-54
pubmed: 26328026
ESMO Open. 2022 Dec;7(6):100591
pubmed: 36208496
Ther Adv Med Oncol. 2020 Jul 07;12:1758835920936932
pubmed: 32684988
J Hepatol. 2019 Jul;71(1):91-103
pubmed: 30930222
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Immunity. 2017 Oct 17;47(4):789-802.e9
pubmed: 29045907
J Hepatocell Carcinoma. 2022 Jul 09;9:595-607
pubmed: 35845819
J Transl Med. 2020 Aug 6;18(1):306
pubmed: 32762721
J Hepatol. 2020 Jan;72(1):167-182
pubmed: 31449859
Front Oncol. 2021 Dec 17;11:803133
pubmed: 34976841
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Clin Oncol. 2021 Sep 20;39(27):2991-3001
pubmed: 34292792
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339
pubmed: 35403533
Expert Opin Investig Drugs. 2022 Apr;31(4):361-369
pubmed: 34798793
Drugs. 2022 Jun;82(8):925-931
pubmed: 35543970
Hepatology. 2022 Oct;76(4):1000-1012
pubmed: 35313048
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33563773
Gastroenterology. 2017 Oct;153(4):1107-1119.e10
pubmed: 28648905
Clin Cancer Res. 2012 Jul 1;18(13):3686-96
pubmed: 22577059
Cell. 2021 Jan 21;184(2):404-421.e16
pubmed: 33357445
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221078476
pubmed: 35226515
Lancet Oncol. 2021 Jul;22(7):977-990
pubmed: 34143971
Cancer Lett. 2015 Dec 1;369(1):242-9
pubmed: 26325606
Cancer Discov. 2022 Aug 5;12(8):1960-1983
pubmed: 35723626
Ann Oncol. 2021 Mar;32(3):395-403
pubmed: 33276076
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32847986
J Clin Oncol. 2023 Feb 20;41(6):1200-1212
pubmed: 36223558
Gut. 2015 Oct;64(10):1593-604
pubmed: 25608525
Target Oncol. 2022 Jan;17(1):61-68
pubmed: 34894318
Hepatology. 2012 Oct;56(4):1342-51
pubmed: 22505239
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543
pubmed: 33850328
Cancer Immunol Res. 2014 Jul;2(7):632-42
pubmed: 24838938
Front Immunol. 2017 May 22;8:572
pubmed: 28588576
Front Oncol. 2021 May 28;11:663264
pubmed: 34123821
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
J Hepatol. 2020 May;72(5):896-908
pubmed: 31887370